Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
205.00
+1.68 (+0.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
46
47
Next >
Thoughts For Thursday: Staying On Top - Barely
November 09, 2023
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago.
Via
Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
November 08, 2023
BIIB earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
November 08, 2023
Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 08, 2023
Via
Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
November 08, 2023
Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023.
Via
Talk Markets
Looking Into Biogen's Recent Short Interest
November 06, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
November 01, 2023
Via
Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
October 30, 2023
Via
Benzinga
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
November 08, 2023
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
November 08, 2023
The company shares in the profits and sales related to Alzheimer's treatment, Leqembi.
Via
Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
November 06, 2023
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
October 18, 2023
Via
Benzinga
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry
October 16, 2023
Via
Benzinga
BIIB Stock Price Analysis: To Bet Or To Fold The Cards
October 14, 2023
Massachusetts-based Biogen (BIIB) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system.
Via
Talk Markets
Analyst Ratings for Biogen
October 11, 2023
Via
Benzinga
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation
From
Biogen Inc.
Via
GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
October 26, 2023
Both companies are working on under-the-skin injections for Alzheimer's treatment.
Via
Investor's Business Daily
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
October 25, 2023
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau,
Via
Benzinga
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week
October 24, 2023
Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 23, 2023
Via
Benzinga
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
3 Struggling Stocks Investors Shouldn't Buy on the Dip
October 18, 2023
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.
Via
The Motley Fool
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
The U.S.
Via
Benzinga
7 Low-Volatility Stocks to Buy if You’re a Concerned Investor
October 11, 2023
With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks.
Via
InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:
Via
Benzinga
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
October 07, 2023
Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.